Lars Johansson, CSO, and Edvin Johansson, Senior MR Imaging Director at Antaros Medical, have been invited to speak later this week at the Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) Regulatory & Trials Update Workshop. They will be giving presentations as part of the ‘Muscle wasting in weight loss therapy’ programme.
There are many methods for assessing weight and body composition in clinical trials, including imaging methods such as dual-energy x-ray absorptiometry (DXA or DEXA) and magnetic resonance imaging (MRI). Each method measures body composition differently, therefore providing different endpoints and suiting different clinical trial contexts and research questions.
The details for the presentations are below:
Title: Assessment of lean body mass (fat free mass) versus muscle volumes and composition in weight loss studies
Presenter: Lars Johansson
Session: Incretins and muscle loss
Friday, December 6 9:30-12:30 EST
Title: Considerations regarding definitions of endpoints in body composition imaging outside DXA
Presenter: Edvin Johansson
Session: Incretins and muscle loss
Friday, December 6 9:30-12:30 EST
The SCWD Regulatory & Trials Update Workshop takes place on December 5-6 in Washington D.C. prior to the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders.
About the SCWD Regulatory & Trials Update Workshop
Bringing together key leaders from regulatory agencies, industry and academia, the workshop will address critical topics related to cancer cachexia, sarcopenia, and muscle wasting, particularly in the context of weight loss therapies. This two-day event will focus on regulatory issues such as studies populations and endpoints in order to pave the way for future clinical trials and research in the field.